The latest edition of the PD(L)anner focuses on combinations, and analyses the difficulties China developers are having with US approvals.
With $219bn in accumulated sales the Abbvie mega-blockbuster is biopharma’s best-selling drug. Can Keytruda do better?
Device approvals hit a nine-year low in 2022, as the FDA takes its foot further off the gas.
After a bruising few months for GSK, 17 global drug makers now have a higher market cap than the UK company.
Orthopaedics and cardiology groups start to improve in terms of sales per employee, but Covid test makers do better still.
The market’s reaction to positive clinical data has largely held up through the downturn, but failures have really, really hurt.
The latest edition of the PD(L)anner provides key updates and details upcoming global events in immuno-oncology.
Increased headcount should allow the FDA to up the number of approvals – but not quite yet.